MCID: LPD008
MIFTS: 64

Lipid Metabolism Disorder

Categories: Genetic diseases, Immune diseases, Liver diseases, Metabolic diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Lipid Metabolism Disorder

MalaCards integrated aliases for Lipid Metabolism Disorder:

Name: Lipid Metabolism Disorder 12 15
Dyslipidemia 12 55 15
Disorder of Fatty Acid Metabolism 29 72
Abnormality of Lipid Metabolism 29 6
Lipid Metabolism Disorders 43 72
Lipid Metabolism, Inborn Errors 44
Fatty Acid Metabolism Disorder 12
Disorder of Lipid Metabolism 59
Dyslipidemias 72

Classifications:

Orphanet: 59  
Inborn errors of metabolism


External Ids:

Disease Ontology 12 DOID:3146
MeSH 44 D008052
ICD10 33 E71.3
UMLS via Orphanet 73 C0154251
Orphanet 59 ORPHA309005
UMLS 72 C0023772 C0154251 C0242339 more

Summaries for Lipid Metabolism Disorder

MedlinePlus : 43 Metabolism is the process your body uses to make energy from the food you eat. Food is made up of proteins, carbohydrates, and fats. Chemicals in your digestive system (enzymes) break the food parts down into sugars and acids, your body's fuel. Your body can use this fuel right away, or it can store the energy in your body tissues. If you have a metabolic disorder, something goes wrong with this process. Lipid metabolism disorders, such as Gaucher disease and Tay-Sachs disease, involve lipids. Lipids are fats or fat-like substances. They include oils, fatty acids, waxes, and cholesterol. If you have one of these disorders, you may not have enough enzymes to break down lipids. Or the enzymes may not work properly and your body can't convert the fats into energy. They cause a harmful amount of lipids to build up in your body. Over time, that can damage your cells and tissues, especially in the brain, peripheral nervous system, liver, spleen, and bone marrow. Many of these disorders can be very serious, or sometimes even fatal. These disorders are inherited. Newborn babies get screened for some of them, using blood tests. If there is a family history of one of these disorders, parents can get genetic testing to see whether they carry the gene. Other genetic tests can tell whether the fetus has the disorder or carries the gene for the disorder. Enzyme replacement therapies can help with a few of these disorders. For others, there is no treatment. Medicines, blood transfusions, and other procedures may help with complications.

MalaCards based summary : Lipid Metabolism Disorder, also known as dyslipidemia, is related to familial lipoprotein lipase deficiency and chylomicron retention disease. An important gene associated with Lipid Metabolism Disorder is FADS1 (Fatty Acid Desaturase 1), and among its related pathways/superpathways are Metabolism and Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha). The drugs Nifedipine and Mirabegron have been mentioned in the context of this disorder. Affiliated tissues include liver, heart and kidney, and related phenotypes are Decreased free cholesterol and Increased LDL uptake

Disease Ontology : 12 An inherited metabolic disorder that involves the creation and degradation of lipids.

Wikipedia : 75 Lipid metabolism is the synthesis and degradation of lipids in cells, involving the breakdown or storage... more...

Related Diseases for Lipid Metabolism Disorder

Diseases related to Lipid Metabolism Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 629)
# Related Disease Score Top Affiliating Genes
1 familial lipoprotein lipase deficiency 32.6 LPL LIPC APOC3 APOA5
2 chylomicron retention disease 32.4 MTTP APOB APOA1
3 abdominal obesity-metabolic syndrome 1 32.4 PPARG MTTP LEP INS ADIPOQ
4 sitosterolemia 32.3 MTTP HMGCR APOB
5 hyperlipoproteinemia, type iv 32.3 LPL APOC3 APOB APOA5
6 hypolipoproteinemia 32.1 MTTP LPL LPA APOE APOB APOA1
7 hypobetalipoproteinemia, familial, 2 31.6 LPL LPA COG2 CETP APOC3 APOB
8 hyperlipoproteinemia, type v 31.6 LPL INS HMGCR APOE APOB APOA5
9 prediabetes syndrome 31.6 PPARG LEP INS CRP COG2 APOB
10 end stage renal failure 31.3 LEP CRP APOB
11 gestational diabetes 31.0 LEP INS ADIPOQ
12 fatty liver disease 31.0 PPARA LEP INS ADIPOQ
13 3-hydroxyacyl-coa dehydrogenase deficiency 30.9 PPARG PPARA LEP INS ADIPOQ
14 peripheral vascular disease 30.9 LPA CRP APOB APOA1
15 anovulation 30.8 LEP INS CRP
16 hyperlipoproteinemia, type iii 30.7 LPL LPA LIPC LDLR HMGCR COG2
17 sleep apnea 30.7 LEP INS CRP APOE ADIPOQ
18 hyperinsulinism 30.6 LEP INS APOB
19 sleep disorder 30.6 LEP INS CRP
20 liver disease 30.5 PPARA LEP INS ADIPOQ
21 familial partial lipodystrophy 30.5 PPARG LEP INS
22 pancreas disease 30.4 LEP INS CRP
23 amyloidosis aa 30.4 LPA CRP APOA1
24 fatty liver disease, nonalcoholic 1 30.3 PPARA MTTP LEP INS ADIPOQ
25 acanthosis nigricans 30.3 PPARG LEP INS ADIPOQ
26 hyperuricemia 30.3 INS CRP APOB
27 cerebrovascular disease 30.3 LDLR INS CRP APOE APOB APOA1
28 apnea, obstructive sleep 30.3 LEP INS CRP ADIPOQ
29 proteasome-associated autoinflammatory syndrome 1 30.3 PPARG PPARA INS CRP ADIPOQ
30 hypobetalipoproteinemia, familial, 1 30.3 MTTP COG2 APOB
31 huntington disease-like 1 30.2 LPA CETP APOE APOB
32 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 30.2 INS ADIPOQ
33 idiopathic edema 30.2 PPARG PPARA INS ADIPOQ
34 coronary stenosis 30.2 CRP CETP APOE APOB APOA1
35 familial hyperlipidemia 30.1 PPARA LPL LPA LIPC LDLR INS
36 sea-blue histiocyte disease 30.1 LDLR APOE APOB
37 hyperglycemia 30.1 PPARG LEP INS ADIPOQ
38 uremia 30.1 LPL LEP INS CRP APOC3
39 coronary artery anomaly 30.0 LPL LPA HMGCR CRP COG2 CETP
40 stroke, ischemic 30.0 LPA HMGCR CRP COG2 APOE APOB
41 defective apolipoprotein b-100 30.0 LDLR HMGCR APOE APOB
42 hepatic lipase deficiency 30.0 LPL LIPC APOE APOA1
43 gallbladder disease 30.0 INS CETP APOE APOB APOA1
44 tangier disease 29.9 LPL LPA CETP APOE APOB APOA1
45 macular degeneration, age-related, 1 29.9 LIPC CRP CETP APOE APOB
46 aortic valve disease 1 29.9 LPA CRP APOB
47 lipoprotein glomerulopathy 29.8 LPA LDLR APOE APOB
48 hypertension, essential 29.8 LPL LPA LEP INS APOB APOA1
49 aortic atherosclerosis 29.8 LPA LDLR CETP APOE
50 carotid artery disease 29.7 LPA CRP COG2 APOE APOB APOA1

Comorbidity relations with Lipid Metabolism Disorder via Phenotypic Disease Network (PDN):


Hypertension, Essential Intermediate Coronary Syndrome

Graphical network of the top 20 diseases related to Lipid Metabolism Disorder:



Diseases related to Lipid Metabolism Disorder

Symptoms & Phenotypes for Lipid Metabolism Disorder

GenomeRNAi Phenotypes related to Lipid Metabolism Disorder according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased free cholesterol GR00340-A-2 9.7 APOA1 APOA5 APOB APOC3 APOE CETP
2 Increased LDL uptake GR00340-A-1 8.92 APOA1 APOE LDLR LPL

MGI Mouse Phenotypes related to Lipid Metabolism Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.25 ADIPOQ APOA1 APOA5 APOB APOE COG2
2 cardiovascular system MP:0005385 10.23 ADIPOQ APOA1 APOB APOE CRP INS
3 cellular MP:0005384 10.17 ADIPOQ APOA1 APOB APOE FADS1 INS
4 growth/size/body region MP:0005378 10.15 ADIPOQ APOB APOE COG2 HMGCR INS
5 adipose tissue MP:0005375 10.08 ADIPOQ APOE INS LDLR LEP LPL
6 endocrine/exocrine gland MP:0005379 10.06 ADIPOQ APOA1 APOE FADS1 INS LDLR
7 liver/biliary system MP:0005370 9.93 ADIPOQ APOA1 APOB APOE HMGCR INS
8 integument MP:0010771 9.91 ADIPOQ APOA1 APOE INS LDLR LEP
9 mortality/aging MP:0010768 9.73 ADIPOQ APOB APOE FADS1 HMGCR INS
10 muscle MP:0005369 9.28 ADIPOQ APOB APOE INS LDLR LEP

Drugs & Therapeutics for Lipid Metabolism Disorder

Drugs for Lipid Metabolism Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 672)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nifedipine Approved Phase 4 21829-25-4 4485
2
Mirabegron Approved Phase 4 223673-61-8 9865528
3
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
4
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
5
Metformin Approved Phase 4 657-24-9 4091 14219
6
Olmesartan Approved, Investigational Phase 4 144689-63-4, 144689-24-7 130881 158781
7
Nevirapine Approved Phase 4 129618-40-2 4463
8
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
9
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
10
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
11
Nateglinide Approved, Investigational Phase 4 105816-04-4 60026
12
Liraglutide Approved Phase 4 204656-20-2 44147092
13
Sirolimus Approved, Investigational Phase 4 53123-88-9 6436030 5284616 46835353
14
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
15
Bilberry Approved, Experimental Phase 4
16
Methylcobalamin Approved, Experimental, Investigational Phase 4 13422-55-4
17
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
18
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
19
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
20
tannic acid Approved Phase 4 1401-55-4
21
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
22
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
23
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
24
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
25
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
26
Polyestradiol phosphate Approved Phase 4 28014-46-2
27
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
28
Ciprofibrate Approved, Investigational Phase 4 52214-84-3 2763
29
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
30
Loperamide Approved Phase 4 53179-11-6 3955
31
Calcium polycarbophil Approved Phase 4 126040-58-2
32 Orange Approved Phase 4
33
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
34
Lopinavir Approved Phase 4 192725-17-0 92727
35
Infliximab Approved Phase 4 170277-31-3
36
Bexarotene Approved, Investigational Phase 4 153559-49-0 82146
37
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
38
Glyburide Approved Phase 4 10238-21-8 3488
39
Febuxostat Approved Phase 4 144060-53-7 134018
40
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
41
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
42
Insulin glargine Approved Phase 4 160337-95-1
43
Alendronate Approved Phase 4 66376-36-1, 121268-17-5 2088
44
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
45
Fluvoxamine Approved, Investigational Phase 4 54739-18-3 3404 5324346
46
Repaglinide Approved, Investigational Phase 4 135062-02-1 65981
47
Dulaglutide Approved, Investigational Phase 4 923950-08-7
48
Insulin Aspart Approved Phase 4 116094-23-6 16132418
49
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
50
Insulin Detemir Approved Phase 4 169148-63-4 5311023

Interventional clinical trials:

(show top 50) (show all 1846)
# Name Status NCT ID Phase Drugs
1 Study on the Efficacy aNd Safety of Jinlida Granules in Patients With Inadequately cOntrolled tYpe-2 Diabetes and dysLIpidemia Under liFe Style Intervention (ENJOY LIFE Study) Unknown status NCT02035644 Phase 4 Jinlida granules;placebo granules
2 An Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate Simvastatin 20 mg Plus Omacor 4g Compared to Simvastatin 20 mg Plus Placebo in Subjects With Mixed Dyslipidemia Unknown status NCT00678743 Phase 4 Omacor + simvastatin
3 Comparison of High-Dose Rosuvastatin Versus Low Statin Dose Plus Fenofibrate Versus Low Statin Dose Plus Niacin in the Treatment of Mixed Hyperlipidemia Unknown status NCT01010516 Phase 4 High-dose rosuvastatin;Statin plus fenofibrate;Statin plus niacin ER/laropiprant
4 Effects of Nicotinic Acid Plus Simvastatin Versus Simvastatin Alone on Carotid and Femoral Intima-Media Thickness in Patients With Peripheral Artery Disease (NASCIT)-A Randomized Controlled Trial Unknown status NCT00712049 Phase 4 simvastatin;Nicotinic Acid
5 An Open-label, Randomized, Multi-centre, Phase IVb, Parallel Study Group to Compare the Efficacy and Safety of 5 mg and 10 mg Rosuvastatin Unknown status NCT01613729 Phase 4 Rosuvastatin 5 mg;Rosuvastatin 10 mg
6 Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia by Aripiprazole Add-on Therapy in the Treatment of Schizophrenia and Bipolar Disorder: An Open-Label Trial Unknown status NCT00541554 Phase 4 Abilify (aripiprazole)
7 An Randomized Open Label Trial on the Impact of 24 Weeks of Atorvastatin Therapy on Liver Fat Content and Abdominal Fat Content in Patients With Type 2 Diabetes Combined With High LDL-C and Non-alcoholic Fatty Liver Disease Unknown status NCT01720719 Phase 4 atorvastatin;Vitamin E
8 The Metabolic and Anti-Inflammatory Effects of Combined Ezetimibe and Simvastin Therapy, as Compared to Simvastatin Alone, in Patients With Chronic Proteinuric Nephropathy Unknown status NCT00861731 Phase 4 simvastatin;EZE/simvastatin;EZE/simvastatin
9 What is the Effects of Incretin on the Blood Pressure and Lipid in Overweight or Obese Diabetes Patients With Masked Hypertension: Liraglutide Plus Mitiglinide Comparing Metformin Plus Mitiglinide or Mitiglinide Alone(BLOOD STUDY) Unknown status NCT02503943 Phase 4 "Liraglutide" and "Mitiglinide";"Metformin" and "Mitiglinide";"Mitiglinide"
10 Comparison of Vascular Remodeling Between Different Antianginal Medication Evaluated by Noninvasive ECG-gated Fundus Photographic Evaluation Unknown status NCT01162902 Phase 4 Diltiazem treated group;Bisoprolol treated group;Candesartan treated group
11 The Effect of Exenatide on Brown Adipose Tissue Activity and Energy Expenditure in Healthy Young Men Unknown status NCT03002675 Phase 4 Bydureon
12 Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients Unknown status NCT02933788 Phase 4 Cilostazol;Acetylsalicylic acid
13 Effect of Vitamin D on Metabolic Parameters in Patients With the Metabolic Syndrome Unknown status NCT01237769 Phase 4 Vitamin D3
14 What is the Effects of Prokinetic Drug on the Blood Glucose in Type 2 Diabetes Patients: Mosapride Comparing Placebo Unknown status NCT02606617 Phase 4 Mosapride;Placebo
15 A Randomized Controlled Study of Nifecardia SRFC (Nifedipine) and Adalat OROS (Nifedipine) in the Treatment of Patients With Essential Hypertension Unknown status NCT00173667 Phase 4 Nifedipine 30 mg GITS
16 Acute Effects of an Oral Fat Load on Skeletal Muscle and Hepatic Insulin Sensitivity (FLAME-study) Unknown status NCT01736202 Phase 4
17 Effects of Growth Hormone on Body Fat Distribution, Insulin Action and Cardiovascular Risk Factors in Middle-Aged Men With Metabolic Syndrome Unknown status NCT00307411 Phase 4 Growth hormone
18 A Randomized Controlled Trial Comparing Usual Care With a Multifactorial Intensified Intervention on Cardiovascular Risk Factors in Subjects With Arterial Peripheral Disease With and Without Diabetes. The Taulí Intervention Program (TIP). Unknown status NCT00144937 Phase 4 Stepwise therapy for dyslipidemia, hypertension and diabetes
19 A Multicenter, Open Labeled, Cross-Over Designed Prospective Study Evaluating the Effects of Lipid Lowering Treatment on Steroid Synthesis Unknown status NCT00433823 Phase 4 Atorvastatin, Ezetimibe
20 A Prospective, Open-label, Parallel, Controlled Study to Evaluate the Efficacy of Fenofibrate on Microalbuminuria in Hypertriglyceridemic Patients With Type 2 Diabetes on Top of Statin Therapy Unknown status NCT02314533 Phase 4 fenofibrate
21 The Effects of Pravastatin and Rosuvastatin on the Tissue Characteristics and Morphology of Coronary Plaques in Patients With Stable Angina Pectoris Unknown status NCT01325818 Phase 4 pravastatin, rosuvastatin
22 Safety and Efficacy of Angiotensin Receptor Blocker, Fimasartan, on Patients With Aortic Stenosis Unknown status NCT01589380 Phase 4 Fimasartan;Placebo
23 The Effect of Mirabegron on Brown Adipose Tissue in Healthy Young White Caucasian and South Asian Men Unknown status NCT03012113 Phase 4 Mirabegron;Placebo Oral Capsule
24 The Low HDL On Six Weeks Statin Therapy (LOW) Study Unknown status NCT00238004 Phase 4 Nicotinic acid
25 The ACT-OUT Trial: ACTivity OUTcomes Based on the Consumption of a High Carbohydrate or High Fat Diet in Patients With Metabolic Syndrome Unknown status NCT01357382 Phase 4
26 Open Label Study Evaluating The Use Of Combination Therapy Of Ezetimibe And Statins In Patients With Dyslipidemia In Colombia Completed NCT00651963 Phase 4 ezetimibe
27 A 12-week, Multicenter, Double-blind, Double-dummy, Randomized, Active-controlled, Parallel-group Study to Assess the Efficacy and Safety of Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily Compared to Fluvastatin Sodium Immediate Release Capsules 40 mg Twice Daily (BID) in Chinese Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia at Moderate or High Cardiovascular Risk Who Did Not Achieve Their Lipid Goals When Treated With Fluvastatin Sodium Immediate Release Capsules 40 mg QD Completed NCT01551173 Phase 4 Fluvastatin sodium
28 The Effect of Fibrate Therapy in Two Patients With Neutral Lipid Storage Disease With Myopathy (NLSDM) Completed NCT01527318 Phase 4 Fibrate treatment
29 Effect of PPAR-Delta Agonist on Lipoprotein Kinetics in Metabolic Syndrome Completed NCT00841217 Phase 4 GW501516;placebo pill
30 Ezetimibe Reverse Cholesterol Transport (RCT) Pilot Study Completed NCT00701727 Phase 4 ezetimibe;Placebo
31 Begin With The Right Patients With Dual-Inhibition Action Therapy Through Vytorin for Newly Diagnosed Dyslipidemia Patients Completed NCT00654628 Phase 4 ezetimibe (+) simvastatin
32 Trial to Evaluate the Efficacy of Fluvastatin on Certain Markers Completed NCT00171262 Phase 4 Fluvastatin
33 A 12-Week, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects With Dyslipidemia, Followed by a 40-Week Safety Extension Study Completed NCT01301066 Phase 4 Pitavastatin;Pravastatin
34 A RANDOMIZED, DOUBLE-BLIND, ACTIVE CONTROLLED, PARALLEL GROUP STUDY OF PITAVASTATIN 4 MG VS. PRAVASTATIN 40 MG IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA Completed NCT01256476 Phase 4 pitavastatin;pravastatin
35 Assessment of the Efficacy and Tolerability of Two Formulations of Atorvastatin In Korean Adult With Hypercholesterolemia : A Multicenter, Prospective, Open-Label, Randomized, Trial Completed NCT01285544 Phase 4 Atorvastatin (Lipinon);Atorvastatin (Lipitor)
36 A Multi-center, Randomized, Double-blinded Equivalence Clinical Trial to Evaluate Efficacy and Safety of LipiLou 20 mg Versus Lipitor 20 mg in Hypercholesterolemic Patients With Higher Risk Cardiovascular Disease in Korea Completed NCT01029522 Phase 4 Atorvastatin (Lipilou);Atorvastatin (Lipitor)
37 Efficacy and Tolerability of Fluvastatin in Adults With Dislipidemia With History of Muscle Problems Due to Other Previous Statin Intake Completed NCT00125125 Phase 4 Fluvastatin
38 A Multicenter, Pragmatic Randomized, Double-blind, Placebo-controlled Trial of Xuezhikang Capsule for Treating Dyslipidemia: a Postmarketing Study Completed NCT02057302 Phase 4 Xuezhikang capsule
39 Efavirenz to Nevirapine Switch in HIV-1 Infected Patients With Severe Dyslipidemia: A Randomized Controlled Study Completed NCT00405171 Phase 4 Nevirapine
40 A 16-week Multicenter, 2-period Study to Investigate the Effect of the Combination of Fluvastatin ER 80mg and Fenofibrate 200mg on HDL-C in Comparison to the Combination of Simvastatin 20mg and Ezetimibe 10mg in Patients With Metabolic Syndrome Completed NCT00385658 Phase 4 Fluvastatin extended release, fenofibrate;Fixed combination simvastatin/ezetimibe
41 Metformin for Treatment of Antipsychotic-induced Dyslipidemia: a Randomized, Double-blind Study Completed NCT01778244 Phase 4 metformin
42 An Outcome Research on the Impact of a Disease Management Program (COACH) on the Attainment of Better Cardiovascular Risk Control in Dyslipidemic Patients at Primary Care Centers (DISSEMINATE). Completed NCT00708370 Phase 4
43 A Multi-center, Open-label, Randomized, Active-control, Parallel-group Designed Study to Compare Effects of Nateglinide and Acarbose on Postprandial Status in Chinese Drug-naive Type 2 Diabetes Mellitus Patients Completed NCT00928889 Phase 4 Nateglinide 120 mg;Acarbose 50 mg
44 Efficacy and Safety of Fluvastatin 80 mg or Valsartan 160 mg and Their Combination in Dyslipidemic Patients With Arterial Hypertension and Endothelial Dysfunction Completed NCT00171327 Phase 4 valsartan, fluvastatin
45 Neointimal Coverage After Implantation of Biolimus Eluting Stent With Biodegradable Polymer: Optical Coherence Tomographic Assessment According to the Treatment of Dyslipidemia and Hypertension and the Types of Implanted Drug-eluting Stents Completed NCT01502904 Phase 4 pravastatin 20mg/day after DES implantation;pitavastatin 2mg/day after DES implantation;Non-ARB /day after DES implantation;Eposartan 600mg/day after DES implantation
46 A 12-Week, Double-Blind, Randomized, Placebo-Controlled Study to Assess the LDL Cholesterol Lowering and Anti-Hyperglycemic Efficacy of Welchol® (Colesevelam) in Subjects With Impaired Fasting Glucose Who Are Taking Niaspan® (Niacin) for Dyslipidemia Completed NCT01239004 Phase 4 Placebo;Colesevelam
47 A 8-week, Single Center, Randomized, Open-label, Parallel-group, Non-inferiority Clinical Trial to Evaluate Efficacy and Safety of ROVASRO 10mg Versus CRESTOR 10mg in Hypercholesterolemic Patients Completed NCT03949374 Phase 4 CRESTOR, reference formulation of rosuvastatin;ROVASRO, generic formulation of rosuvastatin
48 An 8-Week Randomized, Double-Blind, Placebo-Controlled Trial Examining The Efficacy And Safety Of Caduet® In Simultaneously Achieving Blood Pressure And Lipid Goals In An Untreated Hypertensive And Dyslipidemic Subject Population. (CUSP - Caduet in Untreated Subject Population) Completed NCT00332761 Phase 4 Caduet
49 Effects of Pitavastatin on Lipid Profiles in HIV-infected Patients With Dyslipidemia and Receiving Atazanavir/Ritonavir: A Randomized, Double-blind, Crossover Study Completed NCT02442700 Phase 4 pitavastatin;placebo
50 A Phase IV, Randomized, Open-label, Parallel-arm, Comparative and Forced- Titration Study to Compare the Efficacy and Safety of Rosuvastatin Versus Simvastatin in Patients With Type 2 DM and Dyslipidemia Completed NCT00506961 Phase 4 Rosuvastatin;Simvastatin

Search NIH Clinical Center for Lipid Metabolism Disorder

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Bezafibrate
Cholestyramine
Colestipol
Fenofibrate
Fluvastatin
Lovastatin

Cochrane evidence based reviews: lipid metabolism, inborn errors

Genetic Tests for Lipid Metabolism Disorder

Genetic tests related to Lipid Metabolism Disorder:

# Genetic test Affiliating Genes
1 Disorder of Fatty Acid Metabolism 29
2 Abnormality of Lipid Metabolism 29

Anatomical Context for Lipid Metabolism Disorder

MalaCards organs/tissues related to Lipid Metabolism Disorder:

41
Liver, Heart, Kidney, Endothelial, Ovary, Testes, Bone

Publications for Lipid Metabolism Disorder

Articles related to Lipid Metabolism Disorder:

(show top 50) (show all 25005)
# Title Authors PMID Year
1
Obesity and dyslipidemia in patients with psoriasis: A case-control study. 38 17
31374004 2019
2
Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibition: A Lipocrinologic Review. 38 17
31317713 2018
3
Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome. 17
31390500 2019
4
Targeting dyslipidemia in the metabolic syndrome: an update. 9 38
19485929 2010
5
Insulin resistance, dyslipidemia, and metabolic syndrome in women with polycystic ovary syndrome. 9 38
20199774 2010
6
Ala54Thr polymorphism of fatty acid-binding protein 2 gene and fasting blood lipids: a meta-analysis. 9 38
20047744 2010
7
Insulin resistance is associated with C-reactive protein independent of abdominal obesity in nondiabetic Taiwanese. 9 38
20004425 2010
8
Association of low testosterone with metabolic syndrome and its components in middle-aged Japanese men. 9 38
20339372 2010
9
Nuclear receptors as drug targets in cholestasis and drug-induced hepatotoxicity. 9 38
20388526 2010
10
A novel germline mutation in peroxisome proliferator-activated receptor gamma gene associated with large intestine polyp formation and dyslipidemia. 9 38
20123124 2010
11
Fenofibrate antagonizes Chk2 activation by inducing Wip1 expression: implications for cell proliferation and tumorigenesis. 9 38
20226795 2010
12
The effect of PPAR-alpha agonism on apolipoprotein metabolism in humans. 9 38
20005515 2010
13
Is there a link between inflammation and abnormal lipoprotein profile in Sjögren's syndrome? 9 38
20378384 2010
14
Osteoprotegerin in relation to type 2 diabetes mellitus and the metabolic syndrome in postmenopausal women. 9 38
19922962 2010
15
Concordance of two multiple analytical approaches demonstrate that interaction between BMI and ADIPOQ haplotypes is a determinant of LDL cholesterol in a general French population. 9 38
20186155 2010
16
Peroxisome proliferator-activated receptor-delta genotype influences metabolic phenotype and may influence lipid response to statin therapy in humans: a genetics of diabetes audit and research Tayside study. 9 38
20200337 2010
17
Hormone and pharmaceutical regulation of ASP production in 3T3-L1 adipocytes. 9 38
20069551 2010
18
Cardiovascular and metabolic risk profile and acylation-stimulating protein levels in children with Prader-Willi syndrome and effects of growth hormone treatment. 9 38
20173020 2010
19
[Statins in the management of acute coronary syndrome]. 9 38
20387563 2010
20
Liver X receptor activation promotes macrophage-to-feces reverse cholesterol transport in a dyslipidemic hamster model. 9 38
19965597 2010
21
Type 2 diabetes mellitus is characterized by reduced postprandial adiponectin response: a possible link with diabetic postprandial dyslipidemia. 9 38
19922965 2010
22
Bone mineral density and atherosclerosis: the Multi-Ethnic Study of Atherosclerosis, Abdominal Aortic Calcium Study. 9 38
19819456 2010
23
Metabolism and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in humans. 9 38
20016053 2010
24
Pharmacologic inhibition of phospholipid transfer protein activity reduces apolipoprotein-B secretion from hepatocytes. 9 38
19933370 2010
25
Interrelationships of Factor VII activity and plasma leptin with insulin resistance in coronary heart disease. 9 38
19781705 2010
26
[Effects of PPARgamma agonist on dyslipidemia and atherosclerosis]. 9 38
20158099 2010
27
Genetic association and interaction analysis of USF1 and APOA5 on lipid levels and atherosclerosis. 9 38
19910639 2010
28
Bezafibrate induces myotoxicity in human rhabdomyosarcoma cells via peroxisome proliferator-activated receptor alpha signaling. 9 38
19683050 2010
29
Development of apolipoprotein B antisense molecules as a therapy for hyperlipidemia. 9 38
20425272 2010
30
The common biological basis for common complex diseases: evidence from lipoprotein lipase gene. 9 38
19639021 2010
31
[Prevalence of cardiovascular disease in uraemia and relevance of cardiovascular risk factors]. 9 38
20514101 2010
32
Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia. 9 38
20104931 2010
33
Serum fibroblast growth factor 21 levels in gestational diabetes mellitus in relation to insulin resistance and dyslipidemia. 9 38
19699495 2010
34
Expression of human apoAII in transgenic rabbits leads to dyslipidemia: a new model for combined hyperlipidemia. 9 38
19778946 2009
35
Effects of weight loss on lipid transfer proteins in morbidly obese women. 9 38
19789902 2009
36
Decrease in FASN expression in adipose tissue of hypertensive individuals. 9 38
19851294 2009
37
[A case-control study on risk factors of type 2 diabetes mellitus related chronic complications in Baoding city]. 9 38
20193318 2009
38
Decreased PPAR gamma expression compromises perigonadal-specific fat deposition and insulin sensitivity. 9 38
19749155 2009
39
Deletion of protein tyrosine phosphatase 1b improves peripheral insulin resistance and vascular function in obese, leptin-resistant mice via reduced oxidant tone. 9 38
19797171 2009
40
Serum retinol-binding protein 4 correlates with obesity, insulin resistance, and dyslipidemia in HIV-infected subjects receiving highly active antiretroviral therapy. 9 38
19501863 2009
41
Functional variant disrupts insulin induction of USF1: mechanism for USF1-associated dyslipidemias. 9 38
20031629 2009
42
[Secondary dyslipidaemia after oral contraceptives]. 9 38
19947236 2009
43
ACP1 genotype, glutathione reductase activity, and riboflavin uptake affect cardiovascular risk in the obese. 9 38
19570551 2009
44
Forkhead box transcription factor O1 inhibits cholesterol 7alpha-hydroxylase in human hepatocytes and in high fat diet-fed mice. 9 38
19463968 2009
45
Adiponectin is associated with cardiovascular disease in male renal transplant recipients: baseline results from the LANDMARK 2 study. 9 38
19821969 2009
46
Increase in gamma-glutamyltransferase level and development of established cardiovascular risk factors and diabetes in Japanese adults. 9 38
19419267 2009
47
Splenomegaly with sea-blue histiocytosis, dyslipidemia, and nephropathy in a patient with lecithin-cholesterol acyltransferase deficiency: a clinicopathologic correlation. 9 38
19592052 2009
48
A systems genetics approach implicates USF1, FADS3, and other causal candidate genes for familial combined hyperlipidemia. 9 38
19750004 2009
49
A unique rodent model of cardiometabolic risk associated with the metabolic syndrome and polycystic ovary syndrome. 9 38
19470707 2009
50
The role of PPARalpha in lipid metabolism and obesity: focusing on the effects of estrogen on PPARalpha actions. 9 38
19646654 2009

Variations for Lipid Metabolism Disorder

ClinVar genetic disease variations for Lipid Metabolism Disorder:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 APOE NM_000041.4(APOE): c.461G> T (p.Arg154Leu) single nucleotide variant Likely pathogenic rs200703101 19:45412014-45412014 19:44908757-44908757

Expression for Lipid Metabolism Disorder

Search GEO for disease gene expression data for Lipid Metabolism Disorder.

Pathways for Lipid Metabolism Disorder

Pathways related to Lipid Metabolism Disorder according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.83 PPARG PPARA MTTP LPL LPA LIPC
2
Show member pathways
12.75 PPARG PPARA LPL LEP HMGCR FADS1
3
Show member pathways
12.61 LPL LDLR APOE APOC3 APOB APOA1
4 12.38 PPARG INS APOE ADIPOQ
5
Show member pathways
12.37 PPARG LEP INS HMGCR ADIPOQ
6
Show member pathways
12.29 LDLR INS CRP APOE APOB APOA1
7
Show member pathways
12.26 LPL LDLR APOE APOC3 APOB APOA1
8
Show member pathways
12.23 MTTP LPL LPA LIPC LDLR CETP
10 11.97 PPARG PPARA LPL LEP INS ADIPOQ
11
Show member pathways
11.78 APOE APOB APOA1
12 11.67 PPARG LPL LDLR INS HMGCR
13 11.59 PPARA LEP ADIPOQ
14 11.58 PPARG PPARA LPL APOC3 APOA5 APOA1
15
Show member pathways
11.47 MTTP LPL LPA LIPC LDLR HMGCR
16
Show member pathways
11.39 MTTP APOB APOA1
17 11.15 PPARA APOC3 APOA5 APOA1
18 11.12 PPARG LEP ADIPOQ
19 11.05 PPARG LEP ADIPOQ
20 10.95 PPARA LDLR HMGCR

GO Terms for Lipid Metabolism Disorder

Cellular components related to Lipid Metabolism Disorder according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum lumen GO:0005788 9.98 MTTP LIPC INS APOE APOB APOA5
2 early endosome GO:0005769 9.88 LDLR APOE APOC3 APOB APOA1
3 collagen-containing extracellular matrix GO:0062023 9.84 APOE APOC3 APOA1 ADIPOQ
4 high-density lipoprotein particle GO:0034364 9.72 LIPC CETP APOE APOA5 APOA1
5 clathrin-coated endocytic vesicle membrane GO:0030669 9.67 LDLR APOE APOB
6 endocytic vesicle lumen GO:0071682 9.63 APOE APOB APOA1
7 intermediate-density lipoprotein particle GO:0034363 9.56 APOE APOC3 APOB APOA1
8 endosome lumen GO:0031904 9.55 INS APOB
9 low-density lipoprotein particle GO:0034362 9.55 LDLR APOE APOB APOA5 APOA1
10 spherical high-density lipoprotein particle GO:0034366 9.52 APOC3 APOA1
11 discoidal high-density lipoprotein particle GO:0034365 9.51 APOE APOA1
12 very-low-density lipoprotein particle GO:0034361 9.43 LPL APOE APOC3 APOB APOA5 APOA1
13 chylomicron GO:0042627 9.1 LPL APOE APOC3 APOB APOA5 APOA1
14 extracellular region GO:0005576 10.22 LPL LPA LIPC LEP INS CRP
15 extracellular space GO:0005615 10.15 LPL LIPC LEP INS CRP CETP

Biological processes related to Lipid Metabolism Disorder according to GeneCards Suite gene sharing:

(show top 50) (show all 83)
# Name GO ID Score Top Affiliating Genes
1 lipid catabolic process GO:0016042 9.99 LPL LIPC APOC3 APOB
2 glucose homeostasis GO:0042593 9.99 PPARG LEP INS ADIPOQ
3 negative regulation of inflammatory response GO:0050728 9.99 PPARA APOE APOA1 ADIPOQ
4 retinoid metabolic process GO:0001523 9.97 APOE APOC3 APOB APOA1
5 cholesterol transport GO:0030301 9.97 LIPC LDLR CETP APOB APOA1
6 cholesterol efflux GO:0033344 9.97 APOE APOC3 APOB APOA5 APOA1
7 high-density lipoprotein particle remodeling GO:0034375 9.96 LIPC CETP APOE APOC3 APOA1
8 phospholipid transport GO:0015914 9.95 MTTP LDLR CETP APOA1
9 low-density lipoprotein particle remodeling GO:0034374 9.95 LPA LIPC CETP APOE APOB
10 cholesterol biosynthetic process GO:0006695 9.94 HMGCR APOE APOA5 APOA1
11 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.93 PPARG PPARA CRP CETP ADIPOQ
12 reverse cholesterol transport GO:0043691 9.93 LIPC CETP APOE APOC3 APOA5 APOA1
13 response to organic substance GO:0010033 9.92 PPARG FADS1 APOB
14 circadian rhythm GO:0007623 9.92 MTTP LEP ADIPOQ
15 response to insulin GO:0032868 9.91 PPARA LEP FADS1
16 positive regulation of lipid biosynthetic process GO:0046889 9.91 INS APOE APOA5 APOA1
17 chylomicron assembly GO:0034378 9.91 MTTP APOE APOC3 APOB APOA1
18 triglyceride homeostasis GO:0070328 9.91 LPL LIPC CETP APOE APOC3 APOA5
19 fatty acid biosynthetic process GO:0006633 9.9 LPL LIPC FADS1
20 glucose metabolic process GO:0006006 9.9 LEP INS ADIPOQ
21 phospholipid efflux GO:0033700 9.9 APOE APOC3 APOA5 APOA1
22 chylomicron remodeling GO:0034371 9.89 LPL APOE APOC3 APOB APOA1
23 negative regulation of MAP kinase activity GO:0043407 9.88 HMGCR APOE ADIPOQ
24 lipid homeostasis GO:0055088 9.88 PPARG CETP APOE
25 chylomicron remnant clearance GO:0034382 9.88 LIPC LDLR APOE APOC3 APOB
26 low-density lipoprotein particle clearance GO:0034383 9.85 LDLR APOB ADIPOQ
27 lipoprotein transport GO:0042953 9.85 PPARG MTTP APOB
28 high-density lipoprotein particle assembly GO:0034380 9.85 APOE APOA5 APOA1
29 very-low-density lipoprotein particle assembly GO:0034379 9.84 MTTP APOC3 APOB
30 negative regulation of blood vessel diameter GO:0097756 9.83 INS HMGCR CRP
31 high-density lipoprotein particle clearance GO:0034384 9.83 LDLR APOE APOA1
32 positive regulation of cholesterol esterification GO:0010873 9.83 APOE APOA5 APOA1
33 regulation of cholesterol transport GO:0032374 9.81 APOE APOA5 APOA1
34 regulation of Cdc42 protein signal transduction GO:0032489 9.81 APOE APOC3 APOA1
35 lipoprotein biosynthetic process GO:0042158 9.8 APOE APOB APOA1
36 regulation of intestinal cholesterol absorption GO:0030300 9.8 LEP APOA5 APOA1
37 very-low-density lipoprotein particle remodeling GO:0034372 9.8 LPL LIPC CETP APOE APOA5 APOA1
38 triglyceride catabolic process GO:0019433 9.8 LPL LIPC APOE APOC3 APOB APOA5
39 lipoprotein catabolic process GO:0042159 9.79 LDLR APOE APOB
40 regulation of fat cell differentiation GO:0045598 9.76 PPARG LEP
41 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.76 LPL APOB
42 positive regulation of insulin receptor signaling pathway GO:0046628 9.76 LEP INS
43 positive regulation of cellular protein metabolic process GO:0032270 9.76 INS ADIPOQ
44 negative regulation of lipid catabolic process GO:0050995 9.76 INS APOC3
45 lipoprotein metabolic process GO:0042157 9.76 PPARA MTTP LDLR APOE APOC3 APOB
46 fatty acid oxidation GO:0019395 9.75 PPARG ADIPOQ
47 fatty acid homeostasis GO:0055089 9.75 INS APOE
48 positive regulation of cholesterol efflux GO:0010875 9.75 APOE ADIPOQ
49 negative regulation of gluconeogenesis GO:0045721 9.75 INS ADIPOQ
50 long-chain fatty acid transport GO:0015909 9.75 PPARG APOE

Molecular functions related to Lipid Metabolism Disorder according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 heparin binding GO:0008201 9.88 LPL LPA LIPC APOE APOB APOA5
2 phospholipid binding GO:0005543 9.85 APOE APOC3 APOB APOA5 APOA1
3 hormone activity GO:0005179 9.77 LEP INS ADIPOQ
4 amyloid-beta binding GO:0001540 9.75 LDLR APOE APOA1
5 phospholipid transporter activity GO:0005548 9.67 MTTP CETP APOA1
6 low-density lipoprotein particle receptor binding GO:0050750 9.67 CRP APOE APOB APOA5
7 low-density lipoprotein particle binding GO:0030169 9.65 LIPC LDLR CRP
8 cholesterol binding GO:0015485 9.65 CETP APOE APOC3 APOA5 APOA1
9 apolipoprotein binding GO:0034185 9.62 MTTP LPL LPA LIPC
10 phosphatidylcholine-sterol O-acyltransferase activator activity GO:0060228 9.61 APOE APOA5 APOA1
11 phospholipase activity GO:0004620 9.58 LPL LIPC
12 lipoprotein particle binding GO:0071813 9.56 APOE APOA1
13 lipase inhibitor activity GO:0055102 9.55 APOC3 APOA1
14 lipid transporter activity GO:0005319 9.55 MTTP CETP APOE APOB APOA1
15 lipase binding GO:0035473 9.54 APOB APOA5
16 high-density lipoprotein particle receptor binding GO:0070653 9.52 APOC3 APOA1
17 triglyceride binding GO:0017129 9.51 LPL CETP
18 cholesterol transporter activity GO:0017127 9.35 CETP APOE APOB APOA5 APOA1
19 lipid binding GO:0008289 9.23 PPARG PPARA MTTP CETP APOE APOC3
20 identical protein binding GO:0042802 10.11 PPARG LDLR INS CRP APOE APOA1

Sources for Lipid Metabolism Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....